SHSE:600196

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Shanghai Fosun Pharmaceutical (Group)

Executive Summary

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. More Details


Snowflake Analysis

Solid track record established dividend payer.


Similar Companies

Share Price & News

How has Shanghai Fosun Pharmaceutical (Group)'s share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 600196's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-6.9%

600196

-2.4%

CN Pharmaceuticals

-1.4%

CN Market


1 Year Return

127.6%

600196

37.5%

CN Pharmaceuticals

28.8%

CN Market

Return vs Industry: 600196 exceeded the CN Pharmaceuticals industry which returned 37.5% over the past year.

Return vs Market: 600196 exceeded the CN Market which returned 28.8% over the past year.


Shareholder returns

600196IndustryMarket
7 Day-6.9%-2.4%-1.4%
30 Day15.3%0.8%1.0%
90 Day15.9%-7.0%-0.9%
1 Year129.2%127.6%39.0%37.5%31.0%28.8%
3 Year40.2%36.1%26.7%22.0%12.9%7.5%
5 Year134.8%121.3%34.2%27.1%14.3%6.6%

Price Volatility Vs. Market

How volatile is Shanghai Fosun Pharmaceutical (Group)'s share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Shanghai Fosun Pharmaceutical (Group) undervalued compared to its fair value and its price relative to the market?

40.6x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: 600196 (CN¥55.76) is trading above our estimate of fair value (CN¥8.31)

Significantly Below Fair Value: 600196 is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: 600196 is poor value based on its PE Ratio (40.6x) compared to the CN Pharmaceuticals industry average (39.6x).

PE vs Market: 600196 is good value based on its PE Ratio (40.6x) compared to the CN market (41.5x).


Price to Earnings Growth Ratio

PEG Ratio: 600196 is poor value based on its PEG Ratio (3.1x)


Price to Book Ratio

PB vs Industry: 600196 is overvalued based on its PB Ratio (4.3x) compared to the CN Pharmaceuticals industry average (3.4x).


Next Steps

Future Growth

How is Shanghai Fosun Pharmaceutical (Group) forecast to perform in the next 1 to 3 years based on estimates from 11 analysts?

13.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 600196's forecast earnings growth (13.1% per year) is above the savings rate (3.3%).

Earnings vs Market: 600196's earnings (13.1% per year) are forecast to grow slower than the CN market (24.1% per year).

High Growth Earnings: 600196's earnings are forecast to grow, but not significantly.

Revenue vs Market: 600196's revenue (12.8% per year) is forecast to grow slower than the CN market (17.6% per year).

High Growth Revenue: 600196's revenue (12.8% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 600196's Return on Equity is forecast to be low in 3 years time (11.4%).


Next Steps

Past Performance

How has Shanghai Fosun Pharmaceutical (Group) performed over the past 5 years?

4.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 600196 has high quality earnings.

Growing Profit Margin: 600196's current net profit margins (12.4%) are higher than last year (9.8%).


Past Earnings Growth Analysis

Earnings Trend: 600196's earnings have grown by 4.6% per year over the past 5 years.

Accelerating Growth: 600196's earnings growth over the past year (32.1%) exceeds its 5-year average (4.6% per year).

Earnings vs Industry: 600196 earnings growth over the past year (32.1%) exceeded the Pharmaceuticals industry 6.1%.


Return on Equity

High ROE: 600196's Return on Equity (9.6%) is considered low.


Next Steps

Financial Health

How is Shanghai Fosun Pharmaceutical (Group)'s financial position?


Financial Position Analysis

Short Term Liabilities: 600196's short term assets (CN¥22.6B) exceed its short term liabilities (CN¥22.5B).

Long Term Liabilities: 600196's short term assets (CN¥22.6B) exceed its long term liabilities (CN¥17.8B).


Debt to Equity History and Analysis

Debt Level: 600196's debt to equity ratio (58.6%) is considered high.

Reducing Debt: 600196's debt to equity ratio has increased from 47.3% to 58.6% over the past 5 years.

Debt Coverage: 600196's debt is not well covered by operating cash flow (13.8%).

Interest Coverage: 600196 earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is Shanghai Fosun Pharmaceutical (Group) current dividend yield, its reliability and sustainability?

0.70%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: 600196's dividend (0.7%) is higher than the bottom 25% of dividend payers in the CN market (0.35%).

High Dividend: 600196's dividend (0.7%) is low compared to the top 25% of dividend payers in the CN market (1.65%).


Stability and Growth of Payments

Stable Dividend: 600196's dividends per share have been stable in the past 10 years.

Growing Dividend: 600196's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonably low payout ratio (28.4%), 600196's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: 600196's dividends in 3 years are forecast to be well covered by earnings (29.3% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.0yrs

Average management tenure


CEO

Yifang Wu (51 yo)

4.33yrs

Tenure

CN¥6,593,000

Compensation

Mr. Yifang Wu has been the Chief Executive Officer and President of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. since June 7, 2016. Mr. Wu serves as the President of Wanbang Biopharmaceuticals Co., Ltd ...


CEO Compensation Analysis

Compensation vs Market: Yifang's total compensation ($USD991.41K) is above average for companies of similar size in the CN market ($USD315.16K).

Compensation vs Earnings: Yifang's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Qiyu Chen
Executive Chairman of the Board10.33yrsCN¥11.30m0.0044%
CN¥ 5.7m
Fang Yao
Executive Co-Chairman of the Board3.75yrsCN¥7.77m0.030%
CN¥ 39.0m
Yifang Wu
President4.33yrsCN¥6.59m0.041%
CN¥ 52.9m
Xiaohui Guan
Senior VP & CFO5.33yrsno datano data
Donghua Wang
VP and GM of Public Affairs Department & Administration Departmentno datano datano data
Kexin Wang
Senior Vice Presidentno datano datano data
Yuqing Chen
Senior Vice Presidentno datano datano data
Jingping Mei
Senior Vice Presidentno datano datano data
Xiaoxian Dong
Senior VPno datano datano data
Aimin Hui
Senior Vice Presidentno datano datano data
Hequn Yin
Senior Vice President1.67yrsno datano data
Mei Ha Kam
Joint Company Secretary0.83yrno datano data

3.0yrs

Average Tenure

51yo

Average Age

Experienced Management: 600196's management team is considered experienced (3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Qiyu Chen
Executive Chairman of the Board10.33yrsCN¥11.30m0.0044%
CN¥ 5.7m
Fang Yao
Executive Co-Chairman of the Board3.75yrsCN¥7.77m0.030%
CN¥ 39.0m
Yifang Wu
President4.33yrsCN¥6.59m0.041%
CN¥ 52.9m
Tin Yau Wong
Independent Non-Executive Director5.33yrsCN¥300.00kno data
Guliang Tang
Independent Non-Executive Director1.33yrsCN¥155.00kno data
Xiaoliang Xu
Non-Executive Director1.33yrsno datano data
Houlin Zhang
Non-Executive Directorno datano datano data
Donghui Pan
Non Executive Director0.33yrno datano data
Ling Li
Independent Non-Executive Director1.33yrsCN¥155.00kno data
Ping Gong
Non Executive Director0.33yrno datano data
Xian Jiang
Independent Non-Executive Director5.33yrsCN¥300.00kno data
Qian Ren
Chairman of Supervisory Committee2.75yrsno datano data

2.8yrs

Average Tenure

51yo

Average Age

Experienced Board: 600196's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
  • Ticker: 600196
  • Exchange: SHSE
  • Founded: 1994
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CN¥127.902b
  • Shares outstanding: 2.56b
  • Website: https://www.fosunpharma.com

Number of Employees


Location

  • Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
  • Building A
  • No. 1289 Yishan Road
  • Shanghai
  • Shanghai Province
  • 200233
  • China

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
600196SHSE (Shanghai Stock Exchange)YesDomestic SharesCNCNYAug 1998
600196XSSC (Shanghai Stock Exchange - Shanghai - Hong Kong Stock Connect)YesDomestic SharesCNCNYAug 1998
2196SEHK (The Stock Exchange of Hong Kong Ltd.)Foreign Shares-Foreign ListedHKHKDOct 2012
SFOS.FOTCPK (Pink Sheets LLC)Foreign Shares-Foreign ListedUSUSDOct 2012
08HHBST (Boerse-Stuttgart)Foreign Shares-Foreign ListedDEEUROct 2012
2196SHSC (Stock Exchange of Hong Kong Limited - Shanghai - Hong Kong Stock Connect)Foreign Shares-Foreign ListedHKHKDOct 2012
2196SZSC (The Stock Exchange of Hong Kong - Shenzhen - Hong Kong Stock Connect)Foreign Shares-Foreign ListedHKHKDOct 2012

Biography

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. researches, develops, manufactures, trades, and sells pharmaceutical products in Mainland China and internationally. It operates in five segments: Pharmaceut ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/22 15:28
End of Day Share Price2020/10/22 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.